Skip to main content

Table 4 Association of HDAC2 expression with various clinicopathological factors

From: Differential expression of histone deacetylases HDAC1, 2 and 3 in human breast cancer - overexpression of HDAC2 and HDAC3 is associated with clinicopathological indicators of disease progression

Characteristic All cases HDAC 2 low (IRS 0–4) HDAC 2 intermediate (IRS 6–8) HDAC 2 high (IRS 9–12) P-valueχ 2-test for trends
All cases 212 (100%) 92 (43.4%) 69 (32.5%) 51 (24.1%) --
Histological type      0.59
Ductal carcinoma/Other 180 (100%) 80 (44.4%) 56 (31.1%) 44 (24.5%)  
Lobular carcinoma 27 (100%) 10 (37%) 10 (37%) 7 (26%)  
Histological grade      <0.001*
G1 60 (100%) 34 (56.7%) 20 (33.3%) 6 (10%)  
G2 92 (100%) 39 (42.4%) 32 (34.8%) 21 (22.8%)  
G3 55 (100%) 17 (30.9%) 14 (25.5%) 24 (43.6%)  
Nodal status      0.04*
negative 130 (100%) 66 (50.8%) 36 (27.7%) 28 (21.5%)  
positive 70 (100%) 23 (32.9%) 28 (40%) 19 (27.1%)  
pT-Stage      0.43
pT1 117 (100%) 52 (44.4%) 41 (35%) 24 (20.6%)  
pT2/pT3 79 (100%) 32 (40.5%) 22 (27.9%) 25 (31.6%)  
pT4 10 (100%) 5 (50%) 3 (30%) 2 (20%)  
Hormone receptor status      0.02*
Hormone receptor positive 163 (100%) 73 (44.8%) 59 (36.2%) 31 (19%)  
Hormone receptor negative 43 (100%) 17 (39.5%) 7 (16.3%) 19 (44.2%)  
HER2 status      0.005*
negative 178 (100%) 83 (46.6%) 55 (30.9%) 40 (22.5%)  
positive 25 (100%) 5 (20%) 9 (36%) 11 (44%)